Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $175 from $160 and keeps a Buy rating on the shares after its Q2 earnings beat. The firm expect iRhythm to see strength following a notable $13M revenue beat fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: